Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Gw906

Preclinical

SShenzhen Salubris Pharmaceuticals Co., Ltd.

Gw906 is one of 34 therapeutic programs targeting Hypertension. It is currently in Preclinical.

1

Indications

4

Total Trials

3

Active Trials

33

Competitors

Pipeline

Status by Indication[2][1]

Indication

HypertensionRecruiting

HypertensionPreclinical

Recruiting

Competition

Competitive Landscape

160 competitors in Hypertension

#DrugCompanyPhaseTrials

Foundayo

Nitrostat

VViatris Specialty LLC

Baxfendy

Alka-Seltzer

HCP1803-3

Hanmi Pharmaceutical Company Limited

SGLT2

PProf. Dr. med. Ingo Eitel

Avastin

Winrevair

Alphagan

Deltavit

HHyundai Pharmaceutical Co., LTD.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Hypertension

NCT07835984

Q1 2029

PreclinicalRecruiting

Hypertension

NCT07879755

Clinical

Trials by Indication[1]

Hypertension4 trials

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GW906 Injection in Chinese Healthy Subjects and Subjects With Mild Hypertension

Completed·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 1·NCT07884461·40 enrolled

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of GW906 (SAL0132) Injection in Patients With Essential Hypertension

Recruiting·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Preclinical·NCT07879755·1,500 enrolled

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of GW906 Injection (SAL0132) Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications

Not yet recruiting·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 2·NCT07835984·560 enrolled

Show 1 more trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GW906 (SAL0132) Injection in Patients With Essential Hypertension

Active, not recruiting·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 2·NCT07835971·319 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Gw906. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gw906. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shenzhen Salubris Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShenzhen Salubris Pharmaceuticals Co., Ltd.

Related News